多西紫杉醇联合卡培他滨治疗蒽环类耐药的转移性乳腺癌

目的 观察多西紫杉醇联合卡培他滨(DC方案)治疗蒽环类耐药的晚期乳腺癌的疗效和安全性.方法 选择32例葸环类耐药的转移性乳腺癌患者,给予DC方案化疗.根据WHO制定的实体瘤客观疗效评价标准和抗癌药物毒性分级(0～Ⅳ)标准评价疗效和不良反应.结果 32例患者共完成126个周期化疗,每例患者的化疗周期数为2～12个,中位化疗周期数4个.完全缓解(CR)1例,部分缓解(PR)14例,稳定(SD)11例,进展(PD)6例,总有效率为46.9%.14例肺转移患者中8例有效,13例肝转移患者中6例有效,7例皮肤软组织转移患者中3例有效,5例淋巴结转移患者中3例有效.32例患者的中位肿瘤进展时间(TTP)为5.6个月.1年生存率为56.3%.主要不良反应为骨髓抑制、手足综合征、恶心、呕吐、腹泻、口腔黏膜炎等,84.4%的患者出现中性粒细胞下降,2例达Ⅳ度骨髓抑制.结论 DC方案治疗转移性乳腺癌的有效率高,不良反应可以耐受,是治疗对蒽环类耐药转移性乳腺癌的有效方案.

Docetaxel and capecitabine combination chemotherapy for patients with anthracycline-resistant metastatic breast cancer

Objective To evaluate the efficacy and safety of docetaxel and capecitabine combination chemotherapy (DC regimen) for patients with anthracycline-resistant metastatic breast cancer. Methods Thirty-two patients with anthracycline-resistant metastatic breast cancer were treated with a decetaxel and capecitabine combination regimen. All patients received oral administration of eapecitabine at a dose of 1250 mg/m2 twice daily,within 30 min after meal on D1 to D14,and intravenous infusion of decetaxel at a dose of 75 mg/m2 on D1. The regimen was repeated every 3 weeks. Results A total of 126 cycles of DC regimen were administered in the 32 cases,with a median of 4 cycles. The overall response rate was 46.9%. Among the 32 patients, there were complete response in 1, partial response in 14, stable disease in 11 and progressive disease in 6 cases. The median time to progression (TIP) was 5.6 months. The one-year survival rate was 56.3%. The effective cases in different metastatic organs were:8 cases in the lung,6 cases in the liver, 3 cases in the soft tissue and 3 cases in the lymph nodes. The common adverse reactions were myelosuppression, hand-foot syndrome, nausea and vomiting. Neutropenia was observed in 84.4% of the patients. Two patients developed degree IV myelosuppression. Conclusion The combination chemotherapy regimen of decetaxel plus capecitabine is well-tolerated and effective for anthracycline-resistant metastatic breast cancer.